New insider activity at Roivant Sciences ( (ROIV) ) has taken place on May 22, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Roivant Sciences has seen notable insider activity as President and Immunovant CEO Eric Venker sold 200,000 shares of the company’s stock. The transaction, totaling $6,054,000, reflects a sizable move by a key executive with leadership roles at both Roivant Sciences and its affiliate Immunovant.
Recent Updates on ROIV stock
Roivant Sciences shares surged over 10%–15% as investors reacted to very strong IMVT-1402 Phase 2b rheumatoid arthritis data and a bullish earnings update on its broader pipeline. TD Cowen and Citi raised targets mainly because 1402 showed high response rates with a clean safety profile, while the company highlighted robust cash, advancing cardiopulmonary and autoimmune programs, and numerous data and regulatory catalysts into 2026 despite acknowledged trial and R&D cost risks.
Spark’s Take on ROIV Stock
According to Spark, TipRanks’ AI Analyst, ROIV is a Neutral.
ROIV scores positively on momentum and pipeline/catalyst setup supported by strong liquidity (cash position and the Moderna settlement), but the overall score is held back by weak current financial performance (large losses, declining revenue, and heavy free-cash-flow burn) and limited valuation support given negative earnings.
To see Spark’s full report on ROIV stock, click here.
More about Roivant Sciences
YTD Price Performance: 42.30%
Average Trading Volume: 5,761,367
Technical Sentiment Signal: Buy
Current Market Cap: $23.2B